Retatrutide (20 mg (lyophilized)) Research Use Only (RUO) Canada About this compound Retatrutide is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously
However, at partial or subtherapeutic doses, patients may feel partial benefits, such as mild appetite suppression and small changes in blood sugar levels and weight loss
While results vary, many clinical trials and real-world reports confirm that GLP-1 medications like Semaglutide can provide sustainable outcomes when integrated into a long-term weight management plan
It lowers the amount of sugar the liver makes and slows down processing, which keeps blood sugar from rising too quickly after a meal
The fact that Ivim Health published data at all - and in a peer-reviewed journal - is a point in their favor compared to competitors who make outcome claims without any published evidence
Appetite may feel normal or slightly reduced